We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App





Transgenic Mouse That Models Immune Disease’s Cytokine Storms Could Point to Treatment Solution for COVID-19

By HospiMedica International staff writers
Posted on 05 Jun 2020
A transgenic mouse developed at Cincinnati Children’s Hospital Medical Center (Cincinnati, OH, USA) to model the deadly childhood immune disease HLH (hemophagocytic lymphohistiocytosis) could play a key role in saving lives during the COVID-19 virus pandemic. More...


The so-called cytokine storm that inundates the bodies of severely ill COVID-19 patients with inflammatory cells produced by the immune system is a common feature of children battling secondary HLH, which happens in patients where initial HLH treatment has not worked. This common clinical feature of both illnesses was noticed by Gang Huang, PhD, one of the inventors of the genetically engineered mouse strain and a cancer pathologist at Cincinnati Children’s. He also noticed that severe COVID-19 disease clinical manifestations are very similar to those seen in transgenic laboratory mice created to faithfully mimic human secondary HLH in the lab. That preclinical laboratory research, some of it in collaboration with researchers in Wuhan, China, helped identify the drug ruxolitinib for treating secondary HLH. The anti-inflammatory drug is also used to treat other blood diseases, including leukemia.

During their work, Huang and researchers in China found other clinical studies involving other diseases where ruxolitinib also had worked well at quieting inflammation, and proceeded to successfully test the drug which dramatically reversed respiratory and multi-system inflammation in severely ill COVID-19 patients. A larger Phase III clinical trial RUXCOVID by Incyte and Novartis is now testing up to 400 severely ill COVID-19 patients with ruxolitinib, according to Huang, and preliminary clinical data from the study is expected during the summer.

“This is the first therapy we know of that appears to work effectively to quiet the cytokine storm and inflammation in severe COVID-19 disease, and there are no significant toxicities to patients who take the drug by two pills a day,” said Huang. “This is critical until we can develop and distribute enough effective vaccine to help prevent people from becoming infected.”

Related Links:
Cincinnati Children’s Hospital Medical Center


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Digital Radiography System (Ceiling Free)
Digix CF Series
Fetal Monitor
BT-380
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Design-science framework integrating CML and LLM pipelines for supply chain risk evaluation. (Gupta I, Konduru H, Correa S, et al. A causal analytics approach for interpretable supply chain risk and supplier performance evaluation. Supply Chain Analytics, 2026. doi:10.1016/j.sca.2026.100248)

Causal AI Tool Withholds Ovarian Cancer Treatment Recommendations When Evidence Insufficient

Ovarian cancer treatment often requires individualized decisions, particularly when available patient data do not clearly favor one therapeutic approach. However, artificial intelligence (AI) systems may... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Medical Imaging

view channel
Image: Overview of the study design, including participant recruitment, multimodal neuroimaging analysis, stage- and cognition-informed feature selection, and development and validation of the DBFG-Net model. CKD-CI, CKD with cognitive impairment; CKD-NCI, CKD without cognitive impairment; HCs, healthy controls; CBF, cerebral blood flow; DBFG-Net, Dual-Branch Feature-Gated Network. (Photo courtesy of Wenbo Yang and Lijun Song, Capital Medical University)

AI Combines Brain Imaging Features to Identify Cognitive Impairment in CKD

Chronic kidney disease (CKD) can affect multiple organs, including the brain, with cognitive impairment emerging as a common complication. Changes in executive function, attention, and memory can reduce... Read more

Health IT

view channel
Image Credit: Shutterstock

Telemonitoring Program Improves Quality of Life After Heart Failure Discharge

Heart failure is a chronic condition associated with high mortality, frequent hospitalizations, and reduced quality of life. Patients face particularly high risks of readmission and death after discharge,... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.